The NPDI collection, which is considered to be one of the most pharmaceutically productive in the world, was constructed with the goal of rapid and easy discovery of medically important compounds. It has a track record of yielding novel bioactive compounds. Some have led to “blockbuster” drugs. The NPDI also has considerable “know-how” regarding the collection’s maintenance, recovery, and follow-up. Three current NPDI scientists researched this collection for decades in its previous pharmaceutical setting. The collection is specifically comprised of more than 22,000 plant, 35,000 actinomycetous, and 45,000 fungal extracts; significant back up samples; and source bacterial and fungal organisms. The NPDI also offers unique genomic DNA samples of its bacterial organisms, providing researchers the opportunity to genetically mine the microbes for their biosynthetic potential.
We also have stocks of purified natural products for research purposes.
- flexible, readily scalable
- can be manipulated (OSMAC)
- virtually infinite in productivity
- result of long evolution
- great complement to microbes
- broad variety of components
Crude and partitioned extracts
- amenable to most assays
- produced in large amounts
- screenable form and chemistry-ready reserves
- require workup, but offer “intact Nature”
“This natural products library is now available to a wider scientific community with the hopes it will assist others in the discovery of new therapies for patients.”
–Tony Ford-Hutchinson, former Merck Senior V.P.